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Abstract
Aims A signiﬁcant proportion of heart failure (HF) patients have HF preserved ejection fraction (HFpEF). The lack of effective
treatments for HFpEF remains a critical unmet need. A key obstacle to therapeutic innovation in HFpEF is the paucity of pre-
clinical models. Although several large animal models have been reported, few demonstrate progression to decompensated
HF. We have established a model of HFpEF by enhancing a porcine model of progressive left ventricular (LV) pressure overload
and characterized HF in this model including advanced cardiometabolic imaging using cardiac magnetic resonance imaging and
hyperpolarized carbon-13 magnetic resonance spectroscopy.
Methods and results Pigs underwent progressive LV pressure overload by means of an inﬂatable aortic cuff. Pigs developed
LV hypertrophy (50% increase in wall thickness, P < 0.001, and two-fold increase in mass compared to sham control, P <
0.001) with no evidence of LV dilatation but a signiﬁcant increase in left atrial volume (P = 0.013). Cardiac magnetic resonance
imaging demonstrated T1modiﬁed Look-Locker inversion recovery values increased in 16/17 segments compared to sham pigs
(P < 0.05–P < 0.001) indicating global ventricular ﬁbrosis. Mean LV end-diastolic (P = 0.047) and pulmonary capillary wedge
pressures (P = 0.008) were elevated compared with sham control. One-third of the pigs demonstrated clinical signs of frank
decompensated HF, and mean plasma BNP concentrations were raised compared with sham control (P = 0.008). Cardiomet-
abolic imaging with hyperpolarized carbon-13 magnetic resonance spectroscopy agreed with known metabolic changes in the
failing heart with a switch from fatty acid towards glucose substrate utilization.
Conclusions Progressive aortic constriction in growing pigs induces signiﬁcant LV hypertrophy with cardiac ﬁbrosis associ-
ated with left atrial dilation, raised ﬁlling pressures, and an ability to transition to overt HF with raised BNP without reduction
in LVEF. This model replicates many aspects of clinical HFpEF with a predominant background of hypertension and can be used
to advance understanding of underlying pathology and for necessary pre-clinical testing of novel candidate therapies.
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Introduction
Heart failure (HF) is the ﬁnal common pathway of a myriad of
metabolic and cardiovascular diseases and imposes a signiﬁ-
cant healthcare burden worldwide. Although there have been
signiﬁcant improvements in clinical management and out-
comes, morbidity and mortality remain high, and there is an
indisputable need for improved treatment options. The path-
ophysiology of HF is complex. Whilst many patients present
clinically as HF with reduced ejection fraction (HFrEF) (≤40%
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EF), a signiﬁcant proportion of HF patients have preserved EF
(HFpEF) demonstrating a reduced ability of the heart to relax
but with EF above 50%.")[OAurl][?–]>")[OAurl][?–]>1 Our re-
cently reported prospective multi-ethnic study shows that
HFpEF accounts for ~30% of all HF cases in parallel New
Zealand and Singapore cohorts. HFpEF is characterized by
older age, a greater prevalence of females, and predominant
background hypertension (78%) compared with HFrEF.")
[OAurl][?–]>")[OAurl][?–]>2 Two year mortality was lower
than HFrEF but still high at 14% and the composite outcome
of all-cause mortality or HF hospitalization occurring in 35%.
Clinical trials in patients with HFpEF have failed to demon-
strate improvements in mortality. A recent meta-analysis ex-
amining data from 25 trials (>18 000 patients) showed no
beneﬁcial effect from angiotensin-converting enzyme inhibi-
tors, angiotensin receptor blocker, or mineralocorticoid antag-
onists on mortality or HF hospitalization.")[OAurl][?–]>")
[OAurl][?–]>3 The lack of effective treatments for HFpEF re-
mains a critical unmet need. A signiﬁcant obstacle to therapeu-
tic innovation in HFpEF is the absence of pre-clinical models
including large animal models that, unlike rodent models, per-
mit detailed instrumentation and extensive imaging and sam-
pling protocols.")[OAurl][?–]>")[OAurl][?–]>4 Although
several large animal models have been reported,")[OAurl][?–
]>")[OAurl][?–]>5 none fulﬁl all the features present in human
disease, and few demonstrate progression to HF. We hypoth-
esized that enhancing a porcine model of progressive left ven-
tricular pressure overload (LVPO)")[OAurl][?–]>")[OAurl][?–]
>6 with greater characterization would demonstrate incipient
HF with some animal progressing to deﬁnitive HF conﬁrming
that this model is suitable for ongoing pre-clinical studies of
HFpEF. Accordingly, we established and enhanced this model
of LVPO and characterized HF in this model with clinical obser-
vations, ﬁlling pressures and BNP measurements and also ad-
vanced cardiometabolic imaging using cardiac magnetic
resonance imaging (CMRI) and hyperpolarized carbon-13mag-
netic resonance (HP13CMR) spectroscopy.
Materials and methods
The study protocol was approved by the Institutional Animal
Care and Use Committees of National University of
Singapore and Biological Research Centre, Agency for Science,
Technology and Research. We built on a previously reported
progressive LVPO model")[OAurl][?–]>")[OAurl][?–]>6 with
key enhancements to progress pigs to evidence-based HFpEF.
Thirty-nine female Yorkshire × Landrace pigs (18–23 kg) were
housed individually receiving standard care.
For echocardiography and CMRI, pigs were pre-medicated
with intramuscular ketamine (Ceva Animal Health, Glenorie
NSW, Australia) (10 mg/kg), atropine (Atrosite, Troy Labora-
tories, Glendenning NSW, Australia) (0.04 mg/kg), and mid-
azolam (Dormicum, Hoffmann-La Roche, Basel, Switzerland)
(0.6 mg/kg), intubated, ventilated, and maintained with inha-
lation isoﬂurane (Attane, Piramal Critical Care, Bethlehem,
PA ). Following Day 0 imaging, pigs were switched to total in-
travenous (i.v.) anaesthesia [midazolam 2.5–4 mg/kg/h,
alfentanil (Rapifen, GlaxoSmithKline, Torrile, Italy) 250–400
μg/kg/h, and pancuronium (Rotexmedica, Trittau, Germany)
0.25–0.3 mg/kg/h] for surgical implantation of aortic cuff.
Other medications included oral amiodarone (Cordarone,
Sanoﬁ-Aventis, Paris, France) (200 mg daily), clopidogrel
(Ceruvin Ranbaxy, Kedah, Malaysia) (75–300 mg), and aspirin
(Cardiprin, Reckitt Benckiser Healthcare, Hull, UK) (100 mg
daily). Pigs also received augmentin (SmithKline Beecham,
Worthing, UK) (15 mg/kg i.v. then 312 mg orally for 5 days)
and fentanyl (Durogesic®, Janssen Pharmaceutica, Beerse,
Belgium) transdermal patches (5 μg/h for 4 days). All pigs
underwent left lateral thoracotomy and pericardiotomy to
isolate the aorta. In 33 pigs, an inﬂatable cuff (Access Tech-
nologies, Skokie, IL, www.norfolkaccess.com) was placed
around the aortic root and connected to an injectable port
tunnelled subcutaneously adjacent to the scapula. Sham pigs
(n = 6) had thoracotomy without cuff placement. Pigs recov-
ered for 1 week prior to commencement of cuff inﬂation.
Pigs underwent weekly echocardiography prior to progres-
sive cuff inﬂation over 4 weeks titrated to achieve incremen-
tal trans-constriction pressure gradients (PGs) of 20, 40, 60,
and 80 mmHg (assessed echocardiographically). From week
4, the PG was maintained at 80 mmHg until completion of ﬁ-
nal magnetic resonance imaging (MRI) and HP13CMR mea-
surements after which pigs were terminated. Cardiac left
ventricle (LV) and lungs were excised, weighed, and samples
taken for subsequent histology. Sham pigs underwent identi-
cal procedures. Trans-thoracic and trans-oesophageal echo
were used to acquire standard cardiac structure and function
measures (Philips EPIQ7 machine). Trans-oesophageal echo,
with tissue Doppler imaging, of the aortic root displayed the
cuff-induced aortic constriction and deﬁned PGs enabling
titration of cuff inﬂation up or down as necessary.
CMRI was performed prior to thoracotomy and repeated
either Day 35 or Day 42 (sham and 2nd half cuff pigs) using
Siemens 3T MRI scanner (MAGNETOM Skyra, Siemens
Healthineers AG, Erlangen, Germany). Standard CMRI protocol
included cine imaging [global and regional LV systolic function
including LV volumes, mass, and LV ejection fraction (LVEF)],
and T1-mapping from Modiﬁed Look-Locker Imaging (MOLLI).
MRI analysis was performed using SEGMENT v2.2 R6338 (http://
segment.heiberg.se). A subset of pigs underwent tandem
CMRI and CMRI hyperpolarizer on Day 42.
HP13CMR spectroscopy was performed in the same scan-
ner as CMRI, using 13C TX quadrature volume coil/13C RX
16-channel ﬂex array coil (Rapid Biomedical, Rimpar,
Germany). [1-13C]pyruvate (7.18 mmol/L; Cambridge Isotope
Laboratories) doped with AH111501 (15 mM) was inserted
into polarizer (SPINLab, GE Healthcare, Chicago, IL) for micro-
wave irradiation. The polarized sample was subsequently
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dissoluted yielding a solution of 250 mmol/L [1-13C]pyruvate
(pH = 7.2–7.7) for immediate injection into animals at a dose
of 0.2 mmol/kg body weight. 13C-MRS started just before i.v.
bolus injection of hyperpolarized [1-13C]pyruvate. The build-
up of metabolites was followed for ~2 min after injection,
with spectra sampled every two heartbeats. Quantiﬁcation
of metabolites was performed using AMARES in the jMRUI soft-
ware package (http://www.jmrui.eu).")[OAurl][?–]>")[OAurl]
[?–]>7,13C-MR spectra were summed over 40 s upon metabo-
lite appearance with peaks ﬁtted for [1-13C]lactate, [1-13C]
pyruvate hydrate, [1-13C]alanine, and [13C]bicarbonate all
normalized to the [1-13C]pyruvate peak.
Ethylenediaminetetraacetic acid blood samples drawn at
baseline and pre-termination were centrifuged, and plasma
was stored at 800C prior to assay for porcine BNP at
Christchurch Heart Institute using a well-validated assay.")
[OAurl][?–]>")[OAurl][?–]>8 A subset of pigs (six sham and
ﬁve cuff) underwent invasive pressure monitoring immedi-
ately after ﬁnal echocardiography. Sheaths were placed in a
jugular vein and carotid artery to allow passing under ﬂuoro-
scopic guidance a Swan Ganz catheter into the pulmonary ar-
tery for measurement of pulmonary capillary wedge pressure
(PCWP) and a ﬂuid-ﬁlled catheter into the LV for measure-
ment of end-diastolic pressure (LVEDP). LV tissue harvested
post-mortem was ﬁxed in buffered 10% formaldehyde prior
to parafﬁn embedding. Picrosirius red staining was performed
by standard methods to allow assessment of myocardial ﬁ-
brosis using automated image analysis (IMAGEJ).
Statistics
Results are expressed as mean + standard error of mean. Pri-
mary analysis was independent t-tests of time-matched data
between the sham and cuff pigs. P < 0.05 was the threshold
for statistical signiﬁcance.
Results
Studies in sham pigs proceeded as planned with data collec-
tion complete. Among the cuff-implanted pigs, three experi-
enced cuff failure (Days 21–28) and were excluded from
analyses. A further ﬁve pigs were excluded due to premature
death (<Day 28) with post-mortems revealing two fatal aor-
tic occlusion deaths (last recorded PG >80mmHg), one aortic
rupture, one with large aortic and LV thrombi, and one pig
died of bacterial pneumonia. A further ﬁve pigs successfully
completed the protocol but exhibited no signiﬁcant increase
in LV mass despite equivalent PGs. Since LV hypertrophy
(LVH) was the primary driver for development of HFpEF,
these pigs were also excluded from further analysis. Twenty
Figure 1 Serial body weight, pressure gradients across aortic arch, left ventricular mass/body weight (LVmass/BW) ratios, and echocardiography de-
rived serial left ventricular dimensions including interventricular septum thickness at diastole, left ventricular posterior wall thickness at diastole
and left ventricular internal diameter at diastole in 20 pigs with progressive inﬂation of aortic cuff to induce left ventricular hypertrophy (●) and six
sham control (◯) pigs. Values shown are mean + standard error of the mean. Signiﬁcant differences at time-matched points between the sham and
aortic cuff to induce left ventricular hypertrophy pigs are indicated as follows: *P < 0.05, **P < 0.01 and ***P < 0.001.
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pigs undergoing aortic cufﬁng completed the full protocol
and developed LVH (cuff-LVH group). Data from this group
are compared to animals undergoing sham procedures.
Both sham and cuff-LVH pigs gained weight throughout
the protocol (Figure ")[OAurl][?–]>")[OAurl][?–]>1). The PG
remained minimal (<6 mmHg) in the sham group but rose
stepwise (in ~20 mmHg increments) over 4 weeks and there-
after remained stable (Figure ")[OAurl][?–]>")[OAurl][?–]>1).
From 2 weeks, LV mass indexed to body weight (LVmass/
BW) increased in the cuff-LVH group to be signiﬁcantly
(~two-fold) higher than sham controls by the end of the study
(Figure ")[OAurl][?–]>")[OAurl][?–]>1). Measures of LV mass
by echocardiography, CMRI, and direct weighing at post-
mortem correlated well. LV wall dimensions were stable in
sham pigs but increased in the cuff-LVH pigs. Thickness of
both interventricular septums and LV posterior walls in dias-
tole increased in the cuffed pigs to be signiﬁcantly higher
than sham by Day 21 and eventually ~50% thicker (Figure ")
[OAurl][?–]>")[OAurl][?–]>1). The LV internal diameter
showed some increase in the cuff group, but the dimension
was only greater than sham at Day 35 (Figure ")[OAurl][?–]
>")[OAurl][?–]>1).
LVEF remained stable with values for both sham and LVH-
cuff group remaining in the 60–65% range (Figure ")[OAurl]
[?–]>")[OAurl][?–]>2). There was no signiﬁcant change in ei-
ther group in LV end-systolic volumes (LVESVs) or LV end-
diastolic volumes (LVEDVs) (Figure ")[OAurl][?–]>")[OAurl][?–
]>2). LV structure and function data measured by CMRI at
baseline and the end of study corroborated changes measured
by echocardiography with no signiﬁcant changes comparing
cuff-LVH to sham pigs for LVEDV, LVESV, stroke volume, LVEF,
cardiac output, or peak ejection rate (Figure ")[OAurl][?–]>")
[OAurl][?–]>3). In contrast, left atrial end-diastolic volume (P
= 0.013 compared to baseline) and peak ﬁlling rate (P < 0.01
compared with sham) increased in the cuff-LVH (Figure ")
[OAurl][?–]>")[OAurl][?–]>3).
Native T1 values derived from MOLLI did not differ signiﬁ-
cantly between sham and cuff-LVH pigs at Day 0 for 16/17
segments of the LV (with the mid-inferior segment the excep-
tion; Figure ")[OAurl][?–]>")[OAurl][?–]>4A). By the end of
study T1 values were signiﬁcantly higher in the cuff-LVH pigs
compared with sham for 16/17 segments with the apical-
lateral segment the sole exception. Picrosirius red staining
of sections from LV free wall (Figure ")[OAurl][?–]>")[OAurl]
[?–]>4B) showed an increase in both interstitial and
perivascular collagen deposition in the tissue from the cuff-
LVH pig with mean intensities measured under a bright ﬁeld
showing a trend for difference and under polarized light be-
ing signiﬁcantly different (P = 0.044) between LVH and sham
groups.
Invasive intra-cardiac pressures (sub-study) showed nor-
mal range pressures in sham pigs, but both PCWP (P =
0.008) and LVEDP (P= 0.047) were raised in cuff-LVH pigs (Fig-
ure ")[OAurl][?–]>")[OAurl][?–]>5). Plasma BNP levels
remained in the normal range in sham control pigs but on av-
erage increased by end of study in the cuff-LVH pigs being sig-
niﬁcantly higher than sham (P = 0.008) and baseline (Day 0)
values (P = 0.02) (Figure ")[OAurl][?–]>")[OAurl][?–]>5). Clini-
cal signs of HF were observed in at least one-third of the pigs
including tachypnea, laboured breathing, cough, lung conges-
tion on auscultation, cyanosis, and lethargy. One pig demon-
strated major falls in arterial oxygen saturation (SPO2 < 40%)
on induction of anaesthesia for Day 35 imaging with extreme
cyanosis and severe pulmonary oedema and pleural effu-
sions. This pig underwent drainage of accumulated pleural
ﬂuid and received additional oxygen therapy and treatment
with 2 mg/kg i.v. frusemide (Furosemide Fresenius Kabi,
Bad Homburg, Germany) before stabilizing and proceeding
to MRI and echo, followed by partial removal of glycerol from
the aortic cuff to stabilize PG. It recovered to survive to end
of the protocol (Day 42).
Representative cardiac 13C-MR spectra after injection of
hyperpolarized [1-13C]pyruvate from a normal (sham) pig
Figure 2 Echocardiography derived serial left ventricular volumes and
ejection fraction in 20 aortic cuff to induce left ventricular hypertrophy
(●) and six sham control (◯) pigs. Values shown are mean + standard er-
ror of the mean.
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Figure 3 Cardiac magnetic resonance imaging derived left ventricular end diastolic volume, end systolic volume, stroke volume, ejection fraction, peak
ﬁlling and ejection rates, cardiac output and left atrial end-diastolic (ED) volume in 20 aortic cuff to induce left ventricular hypertrophy (●) and six sham
control (◯) pigs. Values shown are mean + standard error of the mean. Left atrial end-diastolic volume was signiﬁcantly increased at 42 days compared
with baseline (*P < 0.05) and left ventricular peak ﬁlling rate increased in aortic cuff to induce left ventricular hypertrophy pigs compared with sham
(**P < 0.01).
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demonstrates that [1-13C]pyruvate is metabolized into [1-
13C]lactate, [1-13C]alanine, [13C]bicarbonate via lactate de-
hydrogenase, alanine aminotransferase (ALT), and pyruvate
dehydrogenase (PDH), respectively with metabolic products
visible within 2 min (Figure ")[OAurl][?–]>")[OAurl][?–]>6A).
Compared to sham pigs, cuff-LVH pigs showed increases in
[1-13C]alanine (P < 0.01) and [13C]bicarbonate (P < 0.05)
with no increase in [1-13C] lactate representing ~2.6-fold
and ~6-fold increase in ALT and PDH activity, respectively
(Figure ")[OAurl][?–]>")[OAurl][?–]>6B).
Figure 4 Top panel – cardiac MRI T1MOLLI values across 17 segments of the LV at baseline and end of study in 20 cuff-LVH (●) and 6 sham control (◯)
pigs. Bottom panels – examples on picrosirius red staining of sections of the LV free wall and group mean intensities from sham and cuff-LVH pigs
measured under bright ﬁeld and polarizing light. Values shown are mean + SEM. Signiﬁcant differences at time-matched points between the sham
and cuff-LVH pigs are indicated as follows: *P< 0.05, †P< 0.01 and ‡P< 0.001.
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Discussion
This porcine HFpEF model demonstrates signiﬁcant LVH (dou-
bling of LV mass) without LV dilation similar to that previously
reported.")[OAurl][?–]>")[OAurl][?–]>6 Unique features of
our model that document HF include comprehensive serial
imaging (echocardiography and MRI) clearly demonstrating
global ventricular ﬁbrosis by MRI T1 MOLLI, a signiﬁcant in-
creases in plasma BNP, and signiﬁcantly elevated PCWP and
LVEDP. Hyperpolarized 13C-MR studies showed increased
Figure 5 Top panels – invasive pulmonary capillary (PC) wedge pressure and LV end diastolic pressure in 5 cuff-LVH (●) and 6 sham control (◯) pigs.
Lower panels – plasma B-type natriuretic peptide (BNP) levels in cuff-LVH (●) and sham control (◯) pigs. Values shown are mean + SEM. Signiﬁcant
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ALT and PDH activity in HFpEF pigs. Pigs developed incipient
HF with frequent progression to frank decompensated HFpEF
manifested in clinical symptoms, raised LV ﬁlling pressures
and, in some pigs, frank pulmonary oedema. Taken together,
full characterization of this enhanced LVPO model demon-
strates development of incipient HF with some animals
progressing to overt HF conﬁrming that this provides a clini-
cally relevant model suitable for ongoing preclinical studies
of HFpEF.
Our model is based the porcine LVPO model ﬁrst reported
by Spinale et al.")[OAurl][?–]>")[OAurl][?–]>6 Early develop-
ment was attended by complications that subsequently be-
came infrequent. Most early deaths were incurred in the
early phase of setting up the model. Titration of the cuff
ﬁlling was guided by a combination of factors including de-
gree of LVH, measured PG and PG week–week stability, echo-
cardiographic visualization of cuff constriction blood ﬂow
turbulence, and clinical observations of the pig. PG ‘drift’
above 80 mmHg resulted in two early deaths. Subsequently
high PG (>80mmHg) or rapidly drifting PG (>20mmHg incre-
ments from preceding week) triggered partial cuff release.
There was need for daily clinical observations particularly dur-
ing the latter weeks of the protocol with vigilance for leth-
argy, tachypnea, cough, laboured breathing, and cyanosis.
When present, we responded with supportive therapy (e.g.
frusemide) and/or partial cuff release. All pigs that developed
signiﬁcant LVH over the 5–6 week study period were adjudi-
cated to have pre-clinical, incipient HF with ~one-third de-
compensating to frank HF. This model produces more stable
LVPO-induced HFpEF than our previously published model
in sheep that used an acute onset aortic constriction (supra-
renal) resulting in severe pre-morbid (euthanized) or terminal
HF in all sheep with a variable but short (median 15 days) sur-
vival time.")[OAurl][?–]>")[OAurl][?–]>9
Although CMRI provides superior image resolution, echo-
cardiography is non-invasive and economical. Echocardiog-
raphy was used for frequent serial imaging of changes in
cardiac structure and function. LVmass/BW and LV wall
thickness increased progressively in concert with trans-
constriction PGs. In contrast, LV volumes and LVEF showed
no consistent change, indicating no signiﬁcant LV dilation
and preserved EF. Comparison of MRI and echocardiogra-
phy generally showed equivalence of measurements. MRI
allowed accurate measurement of left atrial volume, which
increased in the cuff-LVH pigs, and assessment of cardiac ﬁ-
brosis. Myocardial ﬁbrosis impinges adversely on cardiac
structure and function through increased myocardial stiff-
ness and diastolic dysfunction,")[OAurl][?–]>")[OAurl][?–]
>10 impaired LV contraction and systolic dysfunction,")
[OAurl][?–]>")[OAurl][?–]>11 arrhythmias,")[OAurl][?–]>")
[OAurl][?–]>12 and impaired coronary blood ﬂow")[OAurl]
[?–]>")[OAurl][?–]>13 and is a powerful indicator of adverse
outcomes in heart disease.")[OAurl][?–]>")[OAurl][?–]>14,15
Spinale/Zile had previously demonstrated LVH in the LVPO
model is associated with increased myocardial stiffness
(three-fold) and total collagen (1.5-fold).")[OAurl][?–]>")
[OAurl][?–]>6 MRI T1 MOLLI results here clearly demon-
strated global increases ﬁbrosis across 16/17 segments of
the LV. Only the apical lateral segment failed to show a de-
ﬁnitive rise in T1 value. Nevertheless, picrosirius red stain-
ing at this site demonstrated signiﬁcant collagen
deposition (Figure ")[OAurl][?–]>")[OAurl][?–]>6), but rather
than representative, it likely underestimated overall ventric-
ular ﬁbrosis in this model.
Invasive pressures measured in a subset of the LVH-cuff
animals indicated elevations of PCWP and LVEDP to levels
equivalent to those observed in mild–moderate clinical
HF. The BNPs are long established biomarkers for the
Figure 6 Metabolic signals from hyperpolarizing 13C magnetic resonance
imaging (A) 13C spectra from a normal (sham) pig and (B) metabolite/py-
ruvate signal from 11 aortic cuff to induce left ventricular hypertrophy (●)
and six sham control (◯) pigs. Values shown are mean + standard error of
the mean. The units are in arbitrary units and normalized to the [1-13C]
pyruvate peak amplitude of each animal. Signiﬁcant differences at time-
matched points between the sham and aortic cuff to induce left ventric-
ular hypertrophy pigs are indicated as follows: *P < 0.05 and **P < 0.01.
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diagnosis and prognosis of HF.")[OAurl][?–]>")[OAurl][?–]>16
We used our well-validated assay for porcine/ovine BNP")
[OAurl][?–]>")[OAurl][?–]>8 to ﬁnd elevated mean BNP
levels with three samples from three pigs in the mild range
(6–10 pmol/L or 21–35 pg/mL) and ﬁve in the moderate–
severe HF range (>10 pmol/L or >~35 pg/mL, range of
39–119 pg/mL). Using the identical assay, sheep with
post-myocardial infarction LV dysfunction have BNP levels
of 10–12 pmol/L (~35–42 pg/mL),")[OAurl][?–]>")[OAurl][?–
]>17 and sheep with LVPO leading to pre-morbid (euthana-
sia) severe HF/death have BNP of 15.3 + 3.6 pmol/L (~53
pg/mL).")[OAurl][?–]>")[OAurl][?–]>9 Thus, levels of BNP
measured in the pigs in this study were indicative of mod-
erate to severe HF.
A highly novel aspect of this study is the HP13CMR imaging.
Advanced cardiometabolic imaging allows detection of novel
structural and metabolic cardiac changes. HP13CMR spectros-
copy allows real-time study of myocardial energetics and sub-
strate utilization to aid in understanding the pathophysiology
of HFpEF and may identify novel therapeutic strategies.
HP13CMR results showed signiﬁcant increases in
hyperpolarized [1-13C]alanine and [13C]bicarbonate levels in
the cardiac tissue of HFpEF pigs. Because these [13C]labeled
metabolite signals of [1-13C]lactate, [1-13C]alanine, and [13C]
bicarbonate are obtained by conversion from the
hyperpolarized injected [1-13C]pyruvate via lactate dehydro-
genase, ALT, and PDH, respectively, we deduced that ALT
and PDH activity increased in the HFpEF pigs. The failing heart
switches its energy source from fatty acids towards glucose,")
[OAurl][?–]>")[OAurl][?–]>18 directed towards glycolysis,
whilst the change in glucose oxidation associated with PDH
ﬂux is related to the stage and pathogenesis of HF.")[OAurl]
[?–]>")[OAurl][?–]>19 In rats with aortic constriction, glucose
oxidation is initially increased, but eventually decreases as
cardiac systolic dysfunction develops.")[OAurl][?–]>")[OAurl]
[?–]>20 This may explain the increase in PDH ﬂux in our HFpEF
pig model. Others have demonstrated that in 8 weeks, from
pressure-overload LVH non-diabetic rats, more active PDH
complex was extracted compared with healthy hearts.")
[OAurl][?–]>")[OAurl][?–]>21 Increased cardiac glucose oxida-
tion is also observed in spontaneously hypertensive rats")
[OAurl][?–]>")[OAurl][?–]>22 and in dogs with pacing-induced
HF.")[OAurl][?–]>")[OAurl][?–]>23 Concomitantly, increased
ALT activity may reﬂect increased supply of amino acids and
nucleic acids for hypertrophic growth.")[OAurl][?–]>")[OAurl]
[?–]>20 Mice with LVH induced by aortic constriction show in-
creased activation of anaplerotic pathways.")[OAurl][?–]>")
[OAurl][?–]>24 Taken together, the HP13CMR results indicate
our porcine HFpEF model displays metabolic changes consis-
tent with HF.
The unmet need for models of HFpEF allowing both eluci-
dation of the biology of this syndrome and providing a test
bed for candidate novel therapies has triggered interest in
developing large animal models of HFpEF. Efforts in this
direction have had varying degrees of success. In addition
to the progressive LVPO model,")[OAurl][?–]>")[OAurl][?–]>6
and our previously described sheep model of acute aortic
constriction, which induced rapid deterioration to
HF/death,")[OAurl][?–]>")[OAurl][?–]>9 others have also
employed aortic constriction in pigs. Acute onset aortic con-
striction beyond the carotid bifurcation resulted in rapid in-
duction of LVH with reduced LVEF and acute HF by Day 7
(including death in 4/22 pigs), which then over 7 weeks
evolved into a compensated phase of concentric LVH with re-
stored cardiac function.")[OAurl][?–]>")[OAurl][?–]>25 Thus,
there is need to induce LVPO in a progressive nature as imple-
mented in this study to induce progressive LVH without sys-
tolic dysfunction. Other authors banded ascending aorta of
minipigs (25–30 kg) but showed no signiﬁcant LVH or change
in left atrial volume or LVEDP over 20 weeks and did not re-
port of plasma BNP. Hence this effort produced no objective
evidence of HF.")[OAurl][?–]>")[OAurl][?–]>26 The Mayo
group showed that renal wrapping of old dogs induced
chronic hypertension with secondary LVH and ﬁbrosis with
impaired LV relaxation but no increase in LV diastolic stiffness
claiming to mimic HFpEF.")[OAurl][?–]>")[OAurl][?–]>27 How-
ever, the requirement for old animals (aged 8–13) makes this
model relatively impractical and expensive.
The traditional rodent deoxy-corticosterone acetate
(DOCA)–salt model has been upscaled to pigs, with variable
results.")[OAurl][?–]>")[OAurl][?–]>28,29 DOCA-salt pigs dem-
onstrated signiﬁcant increases in LV mass and wall thickness
and also left atrial volumes at rest compared with control
pigs.")[OAurl][?–]>")[OAurl][?–]>28 During dobutamine stress,
changes in LVEF and LVESV demonstrated normal contractile
reserve but there were differences in cardiac index and
LVEDV compared to normal pigs indicating inadequate in-
crease in myocardial perfusion reserve during dobutamine
stress perhaps indicating early-stage HFpEF but there was
no change in T1 mapping of ﬁbrosis.")[OAurl][?–]>")[OAurl]
[?–]>28 When DOCA-induced hypertension is combined with
high salt, fat, cholesterol, and sugar diet, pigs develop con-
centric LVH and left atrial dilation with no change in LVEF or
HF symptoms at rest.")[OAurl][?–]>")[OAurl][?–]>29 Whilst
there was some evidence of pressure volume relationship be-
ing perturbed, LVEDP was not elevated unless pigs were chal-
lenged with pacing plus dobutamine. A recently reported
study took an even more complex approach with multiple co-
morbidities modelled by combining streptozocin-induced dia-
betes, renal artery embolization to induce kidney dysfunction
and hypertension, and a high fat/salt diet in six pigs followed
for 6 months.")[OAurl][?–]>")[OAurl][?–]>30 They docu-
mented evidence of systemic inﬂammation, coronary endo-
thelial dysfunction, and a rise in reactive oxygen species
with disruption of nitric oxide along with myocardiocyte stiff-
ness and cardiac ﬁbrosis. This model claimed to be a clinically
relevant model LV diastolic dysfunction and a precursor for
HFpEF, but no pigs demonstrated overt HF. Thus, although
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several large animal models have been proposed, none of
these fulﬁl all the features present in human disease. That be-
ing said, human HFpEF is a complex syndrome with multiple
contributing aetiologies with varying occurrence and severity
of comorbidities. Animal models invariably model some but
not all aspects of pathology, thus, researchers need to select
combinations of pathological features according to the spe-
ciﬁc aims of their study. Many of the models noted above
replicate pre-clinical disease with no objective evidence of
HF; thus, they represent early stages of the disease process
and not HFpEF per se.
In conclusion, we have described a steadily progressive,
but sufﬁciently stable and controllable (via titration of
cuff/constriction) model of LVPO with novel data evidencing
ﬁbrosis based on MRI T1 MOLLI mapping, elevated ﬁlling
pressures, metabolic changes, and progression to frank HF
with prolongation of the model. This is a clinically relevant
model of HFpEF on a predominant background of hyperten-
sion with clear utility in advancing knowledge of underlying
pathophysiology of HFpEF and testing novel candidate
therapies.
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